---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-086629"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:17:38.643938+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Amylyx reports FY2025 net loss of $144.7M; avexitide Phase 3 enrollment complete, topline data Q3 2026

## Summary
- Net loss for FY2025: $144.7M ($1.53/share) vs $301.7M ($4.43/share) in FY2024.
- Phase 3 LUCIDITY trial of avexitide in PBH enrollment complete; topline data expected Q3 2026, potential launch 2027.
- Cash, equivalents, and short-term investments $317.0M at Dec 31, 2025; cash runway into 2028.
- R&D expenses decreased to $90.4M from $104.1M due to lower AMX0035 spending, offset by increased avexitide costs.
- Selected AMX0318 (GLP-1 receptor antagonist) as development candidate for PBH; IND filing targeted 2027.

## SEC filing metadata
- accession: 0001193125-26-086629
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000119312526086629/0001193125-26-086629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000119312526086629/amlx-20260303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-086629
- JSON: https://secwatch.observer/filing/0001193125-26-086629.json
- Plain text: https://secwatch.observer/filing/0001193125-26-086629.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.